Hawthorn Pharmaceuticals, Inc. - Product Pipeline Review - Q1 2011

Global Markets Direct, March 2011, Pages: 21

Hawthorn Pharmaceuticals, Inc. – Product Pipeline Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Hawthorn Pharmaceuticals, Inc. - Product Pipeline Review - Q1 2011” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Hawthorn Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Hawthorn Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Hawthorn Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Hawthorn Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Hawthorn Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Hawthorn Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Hawthorn Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Hawthorn Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Hawthorn Pharmaceuticals, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
Hawthorn Pharmaceuticals, Inc. Snapshot
Hawthorn Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Hawthorn Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Hawthorn Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Hawthorn Pharmaceuticals, Inc. – Pipeline Products Glance
Hawthorn Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase I Products/Combination Treatment Modalities
Hawthorn Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Hawthorn Pharmaceuticals, Inc. – Drug Profiles
haw Nuv15
Product Description
Mechanism of Action
R&D Progress
haw Nuv16
Product Description
Mechanism of Action
R&D Progress
haw S13
Product Description
Mechanism of Action
R&D Progress
haw AD14
Product Description
Mechanism of Action
R&D Progress
haw mAb11
Product Description
Mechanism of Action
R&D Progress
haw mAb12
Product Description
Mechanism of Action
R&D Progress
Hawthorn Pharmaceuticals, Inc. – Pipeline Analysis
Hawthorn Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Hawthorn Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Hawthorn Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Hawthorn Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, 2011
Hawthorn Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2011
Hawthorn Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2011
Hawthorn Pharmaceuticals, Inc. - Phase I, 2011
Hawthorn Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, 2011
Hawthorn Pharmaceuticals, Inc. – Pipeline By Molecule Type, 2011
Hawthorn Pharmaceuticals, Inc., Other Locations

List of Figures
Hawthorn Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, 2011
Hawthorn Pharmaceuticals, Inc. – Pipeline by Stage of Development, 2011
Hawthorn Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, 2011
Hawthorn Pharmaceuticals, Inc. – Pipeline By Therapeutic Class, 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• SunGard - Profile - US
• eBay - Strong Execution
• Ixia - Company Analysis
• Idenix Pharmaceuticals, Inc.
• Insight into Samsung Electronics' Notebook PC Business Model
• Amazon - Point of Realization in 2013?